PLC
ANRO icon

Peapod Lane Capital’s Alto Neuroscience ANRO Stock Holding History

Peapod Lane Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-253,992
Closed -$4.52M – 68
2025
Q4 		$4.52M Sell
253,992
-27,971
-10% -$352K 3.85% 3
2025
Q3 		$1.14M Buy
281,963
+3,106
+1% +$10.3K 1.02% 44
2025
Q2 		$613K Buy
+278,857
New +$664K 0.61% 51

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Peapod Lane Capital's ANRO Position: Q1 2026 in Review

Peapod Lane Capital sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 253,992 shares — an estimated $4.52M sold.

Peapod Lane Capital first reported a position in ANRO in Q2 2025 and held it in 3 quarters. The position peaked at $4.52M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Peapod Lane Capital reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
  • Peapod Lane Capital sold 253,992 Alto Neuroscience shares in Q1 2026, an estimated $4.52M.
  • Peapod Lane Capital first reported a position in Alto Neuroscience in Q2 2025 and held it in 3 quarters.
  • Peapod Lane Capital's Alto Neuroscience position peaked at $4.52M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Peapod Lane Capital's 13F filing for Q1 2026, filed 4 May 2026.